Epigenetic regulators of γ-globin expression

Epigenetic regulators of γ-globin expression are a diverse group of proteins, including transcription factors and chromatin-modifying enzymes, that orchestrate the developmental switch from fetal hemoglobin (HbF, α2γ2) to adult hemoglobin (HbA, α2β2) [1, 4]. Key regulators include the master repressors B-cell lymphoma/leukemia 11A (BCL11A) and Leukemia/lymphoma-related factor (LRF/ZBTB7A), as well as enzymatic components like histone deacetylases 1 and 2 (HDAC1/2), lysine-specific demethylase 1 (LSD1), and DNA methyltransferase 1 (DNMT1) [1, 3, 10]. These proteins often function within multi-protein complexes such as the Nucleosome Remodeling and Deacetylase (NuRD) and Direct Repeat Erythroid Definitive (DRED) complexes to maintain a repressive chromatin state at the γ-globin gene promoters in adult erythroid cells [1, 6, 11]. In patients with β-hemoglobinopathies like sickle cell disease and β-thalassemia, reactivating γ-globin expression to increase HbF levels can compensate for defective or absent β-globin, significantly ameliorating disease severity [1, 11, 20]. Pharmacological targeting of these regulators—using HDAC inhibitors, DNMT inhibitors, or LSD1 inhibitors—aims to disrupt the repressive chromatin environment, thereby inducing HbF production [1, 6, 7, 13]. While promising, therapeutic challenges include achieving erythroid specificity to avoid systemic toxicity and managing potential myelosuppression associated with broad epigenetic modulation [4, 7, 11].

Other names

Fetal hemoglobin regulatorsHbF epigenetic regulatorsγ-globin repressorsHbF inducers (epigenetic)Gamma-globin epigenetic regulators

Reactivation of γ-globin expression through the inhibition of DNA methyltransferases (DNMTs), histone deacetylases (HDACs), or histone demethylases (e.g., LSD1), and the disruption of repressive complexes like NuRD and DRED to promote an open chromatin state at the HBG1/2 promoters [1, 6, 10, 13].